Finally, we found that the JAK-STAT pathway inhibitor Ruxolitinib could not only reverse the ERKi-induced EMT and block expansion of the CSC pool, but also impede ERKi-induced tumor relapse, providing a proof of concept for combination inhibitor approach for treating NSCLC patients harboring aberrant MAPK signaling. This evidence concerns the gene SOAT1 and neoplasm.